Originally introduced for OEE performance tracking, “AVionics” solutions can now be utilized to track overall manufacturing efficiencies, ensure process quality, predict equipment maintenance and detail sustainability parameters. Moorestown, NJ – Antares Vision, global leader in visual inspection systems, track & trace solutions and smart data management, has vastly expanded its portfolio of AI-based production facility software. Originally introduced for OEE performance tracking, the company’s AVionics software solutions can now be utilized to track overall manufacturing efficiencies, ensure process quality, predict equipment maintenance and detail sustainability parameters. By tracking various key performance indicators (KPIs), AVionics streamlines data into a user-friendly dashboard for intuitive operator decision-making. Information collected from production and packaging lines can then be used to improve business processes at all levels – from line-level manufacturing through overarching, enterprise-level metrics development. AVionics is easily installed as an add-on, drop-in module on lines without impacting previously implemented validation procedures, or the performance of existing systems. Antares Vision’s initial AVionics offering was in response to pharmaceutical companies’ desire to leverage data generated to comply with serialization mandates in the US and abroad. The new additions to the AVionics set of solutions are suitable for sectors well beyond pharma. The data intelligence landscape system comprises modules capable of collecting various categories of data – from lines, machines, quality control components, etc – and connecting different equipment and machinery to each other. From there, AVionics integrates with production management software, such as MES and ERP, to monitor performance and maximize efficiencies via 360° management of all generated data. AVionics now consists of five modules that can be implemented either independently or in combination with each other to collect and interpret data. This provides a singular software platform from which various licenses and features can be activated and accessed: AVionics Performance monitors equipment key performance indicators (KPIs), analyses and trends to identify optimal performance at line, plant and company level AVionics Quality collects data from quality controls through statistical checks of processes based on quality and variability; the solution then constructs models and trends to create predictive analyses AVionics Manager controls and optimizes the entire production process (from line or control room) via a centralized storage setup, providing an exchange of input and output data for real-time decisions based on transpiring activities AVionics Maintenance helps improve performance by directing predictive and preventive system technical maintenance AVionics Sustainability collects electricity consumption data and parameters related to a facility’s environmental impact, toward the goal of reducing consumption and waste, improving ROI, and documenting and optimizing the environmental profile of individual products Through artificial intelligence algorithms based on machine-learning processes, AVionics is designed to further enhance system accuracy and reliability over time. The result is a slew of benefits: Constant monitoring of process performance and KPIs on all levels (lines, plants, company) through customizable and user-friendly dashboards, to achieve consistent, comprehensive real-time oversight Coordination of all production departments with targeted actions in real time, to plan and improve current and future activities based on trends and history Continuous improvement through artificial intelligence, granting access to all information needed to quickly make decisions for production planning efficiency A sustainable technology that helps companies reduce consumption and waste, increasing ROI and improving the environmental impact of production “Our data management solutions operate in real time alongside production and quality processes, providing information on useful values to help guide future activities,” says Emidio Zorzella, CEO of Antares Vision. “AVionics envisions a factory-of-the-future digital transformation in which all relevant data are interconnected, aggregated, analysed and used proactively within a smart ecosystem. This level of data analysis can uncover unique opportunities and allow companies to remain highly competitive by utilizing advanced metrics.” # # # About Antares Vision Listed since April 2019 on the Italian Stock Exchange in the AIM Market after a business combination with ALP.I (SPAC promoted by Mediobanca), Antares Vision guarantees the protection of products during their life cycle through visual inspection systems for quality control, Track & Trace solutions for anti-counterfeiting and supply chain control, smart data management for maximized efficiency and customer engagement, in all the most demanding industrial sectors, from pharmaceutical to biomedical devices, from food to beverage, from cosmetics to fashion. Antares Vision reaches over 60 countries in the world with complete and flexible solutions, hardware and software, and related services: four Italian branches (Brescia, Parma, Piacenza, Latina), 12 foreign branches (Ireland, Germany [2], France [2], USA [2], Brazil [2], India, Russia and Hong Kong), two Innovation Centers (Italy and Ireland) and a worldwide network of more than 30 partners. With 20 years of experience in vision technologies, Antares Vision is supplier of 10 of the 20 leading pharmaceutical Companies in the world with more than 25.000 vision systems, that ensure every day product safety and quality, 6.500 inspection checks on production lines and more than 3.500 serialization lines installed all over the world to guarantee the tracking of more than 5 billion products across the whole supply chain. With the aim of continuing and supporting the growth and development strategy, during 2019 participation agreements were finalized with T2 Software, a Brazilian company specialized in smart data management solutions, and Orobix, an Italian company leader in artificial intelligence services, as well as the acquisition of 100% of FT System, leader in control and inspection in the beverage sector. In April 2020, Antares Vision finalized an agreement for the acquisition of 82.83% of Tradeticity, a Croatian company specialized in software management of advanced traceability processes. In 2019 Emidio Zorzella and Massimo Bonardi were awarded the Ernst & Young Entrepreneur of the Year award for innovation. www.antaresvision.com For any further information, please contact: Antares Vision North America Marketing & Communication Fiona Nicklen, fiona.nicklen@antaresvision.com, T. +1 856 206 3230 Antares Vision HQ Marketing & Communication Davide Antonioli, davide.antonioli@antaresvision.com, T. +39 0307283500

High attendance at our webinar - organised as part of SACMI Virtual Interpack 2020 – which took customers-users from all over the world on a tour of the SACMI Tethered Cap Solutions that are four years ahead of both the new EU standards and the market On Tuesday 16th June over 600 users – representing 227 firms from 22 countries all over the globe – attended the webinar “Tethered by SACMI”, part of a broader Interpack 2020 virtual tour. With this new integrated system for tethered caps (i.e. caps that remain attached to the bottle after opening) SACMI anticipates the new regulatory framework, and the market, by 4 years. The advantage of the SACMI line lies in a range of flexible solutions that integrate a new-concept cap feeder with the scoring machine and the cap/anti-tamper band inspection system. High attendance at the webinar reflected huge interest by a market that is gearing up for 2024, when tethered caps are set to become the new industry standard with the coming into force of the EU Directive. The webinar format also gave participants a chance to ask questions in real time. During the meeting, SACMI received over 100 requests for further information. The event also generated considerable interest in the new PFMC (the downstream inspection system, equipped with the CVS CUT unit, which checks for proper anti-tamper band performance). What's more, the entire SACMI Closures, Containers & PET sales team is busy organising one-to-one conference calls with all the users who registered on the platform and requested in-depth info on specific aspects. This initiative sees SACMI strengthen its technological leadership on the Closures market. That leadership will be crucial over the coming months in allowing us to intercept and support our customers' investments decisions, in every corner of the globe. Link to https://www.sacmi.com/en-US/Plastics/Tethered-caps Valentina Gollini Group PR & Communication Dept. SACMI Imola SC Via Selice Prov.le, 17/a 40026 Imola (BO) Italy T +39 0542 607 111 | M +39 347 5216895 Valentina.Gollini@sacmi.it | www.sacmi.com

Global manufacturer lays groundwork to achieve company goals for a more sustainable world Spartanburg, S.C. – Diversified global manufacturer Milliken & Company highlights its journey towards a more sustainable world in the company’s second annual corporate sustainability report. The report gives insight into Milliken’s environmental and social commitments as all global locations work to achieve aggressive sustainability goals by 2025. “Milliken is meeting the demands of a rapidly changing world,” said Halsey M. Cook, president and CEO for Milliken & Company. “We’re driving progress for sustainability, inclusivity, zero waste, safety and more for the betterment of the planet and our company.” Using a comprehensive goal scorecard, the 2019 report shares Milliken’s first year of progress towards the company’s 2025 sustainability goals. First introduced in the 2018 report, these goals encompass planet, products and people, and range from zero waste to landfill to fostering an inclusive community that embraces authenticity in the workplace. “Year one concentrated on laying the groundwork, solidifying our efforts, and setting the stage for continuous improvement over the next five years of our journey, together,” Cook continued. Much of the progress made in 2019 forms a critical foundation from which to achieve wideranging positive impacts. Reducing indexed greenhouse gas emissions by 12.4%, joining the Alliance to End Plastic Waste, increasing diversity within manager-level roles, and tracking 15,055 volunteer hours within our communities are some of the notable achievements. Each year, Milliken assembles a global, diverse team to analyze its performance and progress through the lens of where the company is heading next. Their efforts shape this annual report, which aligns with the Global Reporting Initiative framework and is a standard way for forwardleaning companies to share more about their impact on the world. To view the complete report, click here. About Milliken Milliken has been solving everyday problems with innovative solutions for more than 150 years. Our research, design, and manufacturing expertise reaches across a breadth of disciplines including specialty chemicals, floor covering, healthcare and performance and protective textiles. An unwavering commitment to ethics guides our work to redefine how we add strength and protection to products, how we infuse vibrancy and color into our surroundings, and how we care for the environment. For us, success is when discoveries made within Milliken help us all have more meaningful connections with the world. Discover Milliken at www.milliken.com, and join us on Facebook, Instagram, LinkedIn, and Twitter. MEDIA CONTACT Betsy Sikma Betsy.Sikma@milliken.com 864.909.7908 Mollie Williams mollie@mwilliamscg.com 864.419.6204

Tray sealing specialist Proseal has launched a revolutionary tray positioning system - the first of its kind - that calculates the required tray-spacing set-up parameters for individual tray sealing tool-sets, eliminating the trial and error usually associated with this process. The new patent-pending ProPosition™ feature automatically identifies the best position for trays, to ensure the perfect alignment every time. Its advanced technology provides food manufacturers and processors with a simple one-step tool-set-up, and removes the time consuming and potentially wasteful process of running test trays through the tray sealer to ascertain the best position. Instead operators are guided through the set-up via easy to follow animated instructions on the machine’s touch screen. The system then permanently saves the relevant parameters for each tool, which greatly speeds up product changeovers and avoids operator errors during set-up. ProPosition is fitted as standard to all new Proseal GT platform machines. Additionally, as part of Proseal’s ongoing strategy of futureproofing its equipment, the software can be retrofitted to any pre-existing machines which have the suffix GTe and GTs. “The new ProPosition system showcases our incredible engineering innovation and underlines Proseal’s commitment to being at the forefront of product development and innovation,” comments Paul Watkin, Proseal Systems Development Manager. “This pioneering technology helps to minimise downtime, reduce errors and minimise waste to deliver valuable cost savings that will deliver a fast return on investment.” Founded in 1998, Proseal designs and manufactures high quality tray sealing machines, conveyor systems and sealing tools for food industry markets worldwide. Proseal is part of the JBT family, and together they remain committed to continually supporting customers’ needs. Ends For further information about Proseal’s new ProPosition system, please visit https://www.proseal.com/innovations/proposition/ EDITORIAL ENQUIRIES: Bob Bushby/Kerrie Oxford Nielsen McAllister PR Limited Tel: +44 (0) 1332 293939 Email: info@nmpr.co.uk READER ENQUIRIES: Proseal UK Ltd Tel: +44 (0) 1625 856600 Fax: +44 (0) 1625 856611 Email: info@prosealuk.com Website: www.proseal.com

The Covid-19 crisis puts global production capacity for hygiene products to a severe test. In March Reifenhäuser has temporarily produced metlblown to produce roughly one million face masks a day at its Technology Center. The company has now converted another pilot line for production. The first batch produces 110 metric tons of protective film for a global leading manufacturer for medical coveralls for use in hospitals. The increased demand is currently very high for coveralls worn to treat highly infectious coronavirus patients. This volume is sufficient for about 1.2 million coveralls. Reifenhäuser, the manufacturer of plastics extrusion lines, normally uses the Technology Center to research and develop new applications in collaboration with its customers. One of the available blown-film lines is currently running 24/7, initially until the end of this week. The film protects against infections but allows air exchange which is vital for hospital workers who must wear coveralls for long periods of time. Breathability comes from the pore structure in the material which is produced by a special calcium carbonate addition followed by a stretching process (Reifenhäuser EVO Ultra Stretch). Heino Claussen-Markefka, Managing Director Reifenhäuser Blown Film, explains: “Our intention with this project is to make another contribution to strengthen international production capacity which is currently exhausted, so as to supply a sufficient volume of high-quality protective garments during the coronavirus crisis. And we are delighted to use our pilot lines for this.” The same line type is capable of producing hygienic film for use in diapers, besides certified medical protective film. Ultra Stretch technology can also be used in other advanced applications, such as recyclable All-PE film (PET replacement). The production unit can therefore be used flexibly to respond to a wide variety of market demands outside of an emergency or crisis. Tanja Kühn-Söndgen Presse- und Öffentlichkeitsarbeit Press and Public Relations T +49 2241 23510-480 www.reifenhauser.com

Two years after the introduction of the Super Combi to the industry for compact lines’ solutions, today, Sidel presents a bolder, next-generation solution Super Combi Compact that, as indicated in its name, is even more compact. Allowing up to 30% footprint reduction compared to the previous model, the solution also excites with the efficiency enhancement it assures for still water production thanks to the new filling technology embedded in the Sidel EvoFILL HS Still that guarantees a 30% faster performance. Considering that customers worldwide are seeking for possibilities to optimise resources and space required for production, Sidel has developed a ready-made solution to fit any production site as footprint as well as line integration and planning are important drivers at the very centre of Sidel’s technological advancement. With Super Combi Compact Sidel presents an innovative product designed and engineered to deliver the lowest total costs of ownership (TCO) and production costs per square foot. Growing demand for packaged water “We see that the water category has been seeing an unprecedented growth fuelled by a worldwide increase in demand. Due to consumers’ rising health consciousness paired with the trend towards so called “better-for-you drinks”, the packaged water category has remained at the forefront of consumer purchasing decisions since 2018,” explains Stefano Baini, Product Manager Filling and Super Combi at Sidel, identifying why the company has invested in the development of a compact line solution for still water production. This green trajectory throughout the water category was globally influenced by a large hike in tourism along with extremely warm weathers not only in warm climate countries, but in parts of Western Europe too. Enhanced performance and utmost productivity Similarly to its predecessor, Super Combi Compact is integrating five process steps – preform feeder, blower, labeller, filler/capper and cap feeder – into an all-in-one, smart system. What describes the new solution the best is the continuous top-level performance it provides up to 54,000 bottles per hour (bph) in a reduced space. Furthermore, its ergonomics and the latest technologies support easy access, operation and maintenance while ensuring high end-product quality. The overall higher level of efficiency of the solution is achieved by providing maximum uptime and consistent production output at medium to high speed. Maximum productivity of the line is reached particularly due to improvements at the blowing, filling and labelling stages. To highlight some of the most important improvements, the blower can produce up to 2,700 bph per mould. Furthermore, a robotic arm solution for automatic mould changeover is now available to drastically reduce change-over time and improve safety conditions by not requiring any human intervention. Labelling is assured by a single-aggregate labelling system, ensuring reliable production as well as fast and easy label-reel auto splicing. What’s more, Super Combi Compact’s labeller technology features faster changeovers and easy replacement of parts as well as an automatic label vacuum extractor for maximised uptime. In addition, the labeller can accommodate different labels and technologies (Roll-fed, PSL). The star of the solution – Sidel EvoFILL HS Still filling technology Sidel EvoFILL HS Still without a doubt is the most impressive part of the new Super Combi Compact. This new filler with proportional filling valves, controlled by electro-magnetic actuators, guarantees a 30% faster filling with total control and accuracy when it comes to dosing the liquid into its designated container. The improved and completely dynamic filling technology allows for highest precision in modulating the beverage flow, as the plunger inside the filling valve can individually be moved to an infinite number of positions, resulting in maximum freedom in terms of different beverage types to be filled, and different optimum filling speeds and levels. Furthermore, the new hygienic valve design with no beverage membrane assures beverage quality with no flavour carry-over. EvoFILL HS Still is a simplified solution characterised by fewer components and functions, resulting in less maintenance costs, and a highly reduced filler footprint with less filling valves. Additionally, the filler features an onboard beverage tank further contributing to minimise the required floor space. It might also be equipped with an Integrated Cleaning System (ICS), cutting down on water and chemical consumption for internal cleaning as well as – again – on floor space by rendering the need for an external Cleaning in Place system and additional tanks unnecessary. In total, with saving up to 30% of precious floor space while, at the same time, boosting production efficiency by another 30%, and delivering maximum speeds of up to 54,000 bph, the new Super Combi Compact is a perfect fit for producers of PET bottled water. Stefano Baini concludes: “Its new, compact design and innovative filling technology makes it an ideal solution for maximising production and increasing line efficiency at the best TCO per square foot – allowing producers to make the most of their existing space or new greenfield projects." Find out more www.sidel.com/supercombicompact Contact:‌ ‌ F&H‌ ‌Porter‌ ‌Novelli‌ ‌ Tel:‌ ‌+49‌ ‌(0)‌ ‌89‌ ‌12175‌ ‌123‌ ‌ sidel@fundh.de‌

New €7 million investment in state-of-the-art paper sack converting machine at Mondi's plant in Nyíregyháza, Hungary The machine will increase the plant’s quality, efficiency and service standards to produce high-end and sophisticated paper sacks for food purposes The investment will see 130 million paper sacks produced annually Mondi Nyíregyháza is in the process of seeking certification from HACCP to serve the food, feed, and seed industries 30 June 2020 – Mondi, leading global packaging and paper group, has successfully completed the implementation of a new state-of-the-art paper sack converting machine at its Nyíregyháza site in Hungary. The machine – a Windmöller & Hölscher AD 8320 / AM 8115 – allows the plant to produce a new line of sophisticated paper sacks for food packaging. The site will be capable of producing more than 130 million sacks annually. The Mondi Nyíregyháza plant, which employs more than one hundred people, serves the Hungarian, Romanian, Austrian and Bulgarian market in many industries and sectors. It produces industrial paper sacks (open mouth and valve bags) for applications such as cement, building materials, food-feed-seed, chemicals and pharmaceuticals. “Our goal is to serve our customers’ needs with excellence, so we focused on increasing the plant’s quality and hygiene standard to be able to produce high-end and sophisticated paper sacks for food. This investment means we are able to enhance our operational efficiency, as well as offering shorter delivery times to our customers. Our ambition to open this line did not diminish despite the beginning of the health pandemic. Working with revised health and safety measures in place, I am very proud of my team's determination to execute this project and deliver this complex product portfolio," said Péter Szabó, Managing Director, Mondi Bags Hungária. Due to this €7 million investment, the entire layout and set-up of the Nyíregyháza plant was re-designed in four months, including the storage area, printer area, warehouse, and ink kitchen to increase operational efficiency and safety. The plant is now in the process of seeking the Hazard Analysis and Critical Control Points (HACCP) certification by the end of this year in order to serve the food, feed and seed industry with sacks that meet their high quality and hygiene standards. /ends About Mondi Mondi is a global leader in packaging and paper, contributing to a better world by making innovative, packaging and paper solutions that are sustainable by design. Our business is fully integrated across the value chain – from managing forests and producing pulp, paper and plastic films, to developing and manufacturing effective industrial and consumer packaging solutions. Sustainability is at the centre of our strategy and intrinsic in the way we do business. We lead the industry with our customer- centric approach, EcoSolutions, where we ask the right questions to find the most sustainable solution. In 2019, Mondi had revenues of €7.27 billion and underlying EBITDA of €1.66 billion. Mondi has a premium listing on the London Stock Exchange (MNDI), and a secondary listing on the JSE Limited (MNP). Mondi is a FTSE 100 constituent, and has been included in the FTSE4Good Index Series since 2008 and the FTSE/JSE Responsible Investment Index Series since 2007. www.mondigroup.com About Mondi Paper Bags Mondi Paper Bags, a business segment of Mondi Group, is the leading international producer of industrial paper bags selling more than 5 billion bags per year. Thanks to its broad range of bag specifications, Mondi Paper Bags serves major industries including cement and building materials, chemicals, food, feed and seed. The business segment operates a dense sales and service network, the specialised filling equipment department Natro Tech, as well as its Bag Application Centre, where researchers develop and test innovative packaging solutions. Contact: Judith Wronn Senior Communication Manager, Flexible Packaging & Engineered Materials Tel: +49 151 1771 4692 Email: Judith.Wronn@mondigroup.com Josina van der Velden EMG Tel: +31 164 317 014 Email: jvandervelden@emg-marcom.com

Multi-stakeholder platform connects the glass packaging ecosystem; targets 90% glass collection by 2030. Brussels, 30 June 2020 – With the warm welcome of European Commissioner Virginijus Sinkevičius, glass collection and recycling stakeholders today launched a major material stewardship programme which connects the entire European glass packaging ecosystem to boost bottle-to-bottle recycling. The move comes as efforts to consolidate the European Circular Economy scale up following the adoption of the European Green Deal, the European Union’s new agenda for sustainable growth. Glass has long been a leader in circularity, as an infinitely recyclable packaging material with a collection for recycling rate of 76%. As a pan-European action platform, “Close the Glass Loop” is a bottom-up, collaborative, public-private partnership that aims to boost glass collection rates to 90% by 2030. The initiative gathers twelve European federations representing glass manufacturers, processors, brands, Packaging Recovery Organisations and municipalities. The European founding partners are the European Container Glass Federation (FEVE), European Federation of Glass Recyclers (FERVER), Comité Européen des Entreprises Vins (CEEV), European Federation of Bottled Waters (EFBW), spiritsEUROPE, Soft Drinks Europe (UNESDA), Extended Producer Responsibility Alliance (EXPRA), Producer Responsibility Organisations Packaging Alliance (PROsPA, represented by CITEO), ACR+, Eurocities, Municipal Waste Europe, European Fruit Juice Association (AIJN), and European Association of Food and Vegetable Processors (PROFEL) . To ensure a local implementation of measures and tailored solutions, the European Platform will be working hand-in-hand with national partners in every EU Member State. At today’s online launch event, over 200 participants joined founding partners and national representatives from eleven countries – France, Germany, Italy, Poland, Portugal, Spain, the United Kingdom, Austria, Belgium, Sweden and Ireland – to officially launch the platform and sign off on the European Action Plan. ‘A concrete example of co-creation in the Circular Economy’ Joining the online event through video message, Virginijus Sinkevičius, European Commissioner in charge of the Environment, Fisheries and Oceans, commented: “Glass is a great example of a circular material. You are already achieving outstanding results in waste collection and recycling. But today you show that you want to do more, that you are determined to bring levels up across the EU and seek the room for improvement all along the chain. I am confident that you will complete your mission and make the Close the Glass Loop Platform the springboard to the higher levels of the waste hierarchy.” The European Action Plan, presented by Michel Giannuzzi, President of the European Container Glass Federation (FEVE) at today’s launch event, aims to address structural challenges in the glass collection and recycling chain which are common to most EU countries. With municipalities seen as a key player to mobilise collection, “Close the Glass Loop” will establish a strong partnership with local authorities to expand source-separated glass collection, improve glass collection in large cities and tourist areas and ensure that use, collection and recycling of glass containers is better supported by common guidelines and tools, at all stages of use. Individual action points will range from organizing a Municipalities Roadshow and best-practice workshops, to support pilot projects in densely populated or touristic destinations, develop a roadmap for cullet quality and reinforce cooperation between national stakeholders. The full action plan can be viewed at www.closetheglassloop.eu. Setting out the Action Plan, Michel Giannuzzi, President of the European Container Glass Federation (FEVE), noted: “We have the advantage of working with a material that is 100% and infinitely circular by nature and already a success story in terms of sustainability. The more we recycle glass, the less we litter or rely on virgin resources, while also providing premium packaging in terms of quality preservation, health and safety. Today, 76% of glass packaging in the EU market is collected for recycling – but there is more to be done. We need to fully seize the advantages offered by glass and recycle more and better. And to this end, we need the active commitment of the whole value chain. The level of engagement in ‘Close the Glass Loop’ to date lays really promising grounds for success and I am very much looking forward to the positive impact it will create over time.” A number of National Action Plans from Austria, France, Spain and Sweden were also presented, highlighting the diversity of approaches between EU Member States and emphasising the need to provide tailored action plans at local level. At the same time, it reflects the importance of a coordinated approach on European level, to exchange best practice in order to close the collection gap and improve the quality of recycled glass (cullet). More availability of good quality cullet means a more resource-efficient production process, keeping resources productive in a bottle-to-bottle manufacturing loop and providing a premium level, safe and truly recycled packaging material. The production of glass packaging for food, beverages as well as in the pharmaceutical, perfumery and cosmetics sector with an endlessly recyclable, reusable and permanent material translates in less consumption of natural resources, less waste and less use of energy in line with the Sustainable Consumption and Production Goal (SDG 12). At the same time, glass recycling directly allows the industry to dramatically reduce energy consumption and CO2 emissions, in line with the Climate Action Goal (SDG 13). About Glass Packaging Made of minerals abundant in nature - sand, soda-ash, recycled glass and limestone - glass is a 100% and infinitely recyclable material, manufactured in a one-step process under one roof. The majority of collected glass bottles and jars are used repeatedly to produce new food grade glass packaging in the closed loop system. Each time a bottle or jar is recycled into new containers, energy and raw materials are also saved and less CO2 is emitted. In the EU, by recycling glass, over 12 million tons of raw materials are saved each year and over 7 million tons of CO2 are avoided - equal to taking 4 million cars off the road. We save 2.5% energy and 5% of CO2 for each 10% of glass recycled in the furnace.

Espoma Organic continues to showcase their commitment to the environment with more sustainable packaging alternatives. OSHKOSH, Wis. – Espoma Organic, a lawn and garden brand, continues to showcase their commitment to the environment by replacing fossil-fuel-derived polymers in their packaging with more sustainable alternatives. In response to Espoma Organic’s mission to “develop the finest organic gardening products that work in harmony with nature, grow beautiful gardens and make a greener world for the future,” global packaging company Amcor partnered with the brand to innovate more sustainable packaging and launch a new bio-based polymer package. The polyethylene (PE) film contains 25 percent bio-based material, derived – in this case – from sugar cane. “Espoma’s values are strongly rooted in responsibility to the environment and sustainability. Using a renewable and sustainable source of plastic allows us to continue our long-standing tradition of industry leading innovation while reducing our carbon footprint,” said Jeremy Brunner, General Manager of Espoma Organic. Amcor Flexibles Research and Development Senior Director Priscila Troian explains that the choice is both better for the planet and matters to consumers. “We know consumers increasingly are paying attention to product packaging as they make purchasing decisions,” said Troian. “The use of renewable materials in packaging offers brands a new way to stand out on store shelves while driving down the total carbon footprint of their products.” Amcor continues to develop and use bio-based materials to reduce reliance on fossil-fuel-derived plastic packaging. Amcor’s bio-based PE solution is recycle ready and may be recycled at store drop off locations when clean and dry. It also delivers similar technical properties and product protection to traditional plastics while lowering carbon emissions. In addition to packaging lawn and garden products, applications for Amcor’s film include pet care products, wipes, confectionary and more. The bio-based resin is produced from annually renewable sugar-cane feedstock, diminishing dependency on fossil resources and carbon footprint. Amcor was the first packaging company to commit to developing all its packaging to be recyclable or reusable by 2025, directly addressing a major environmental issue with capability, scale and reach. To learn more about plant-sourced raw material packaging contact Amcor Flexibles North America at northamericaflexibles@amcor.com. About Amcor Amcor is a global leader in developing and producing responsible packaging for food, beverage, pharmaceutical, medical, home- and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve value chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company is focused on making packaging that is increasingly light-weighted, recyclable and reusable, and made using a rising amount of recycled content. Around 50,000 Amcor people generate US$13 billion in sales from operations that span about 250 locations in 40-plus countries. NYSE: AMCR; ASX: AMC Mary Johnson Marketing Communications Director Amcor Flexibles North America (920)527-5134 Mary.Johnson@amcor.com

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU. Data on remdesivir were assessed in an exceptionally short timeframe through a rolling review procedure, an approach used by EMA during public health emergencies to assess data as they become available. From 30 April 2020, the CHMP began assessing data on quality and manufacturing, non-clinical data, preliminary clinical data and supporting safety data from compassionate use programmes, well in advance of the submission of the marketing authorisation application on 5 June. The assessment of the dossier has now concluded with today’s recommendation, which is mainly based on data from study NIAID-ACTT-11, sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), plus supporting data from other studies on remdesivir. Study NIAID-ACTT-1 evaluated the effectiveness of a planned 10-day course of remdesivir in over 1,000 hospitalised patients with COVID-19. Remdesivir was compared with placebo (a dummy treatment) and the main measure of effectiveness was patients’ time to recovery (defined as no longer being hospitalised and/or requiring home oxygen or being hospitalised but not requiring supplemental oxygen and no longer requiring ongoing medical care). Overall, the study showed that patients treated with remdesivir recovered after about 11 days, compared with 15 days for patients given placebo. This effect was not observed in patients with mild to moderate disease: time to recovery was 5 days for both the remdesivir group and the placebo group. For patients with severe disease, who constituted approximately 90% of the study population, time to recovery was 12 days in the remdesivir group and 18 days in the placebo group. However, no difference was seen in time to recovery in patients who started remdesivir when they were already on mechanical ventilation or ECMO (extracorporeal membrane oxygenation). Data on the proportion of patients who died up to 28 days after starting treatment are currently being collected for final analysis. Taking into consideration the available data, the Agency considered that the balance of benefits and risks had been shown to be positive in patients with pneumonia requiring supplemental oxygen; i.e., the patients with severe disease. Remdesivir is given by infusion (drip) into a vein and its use is limited to healthcare facilities in which patients can be monitored closely; liver and kidney function should be monitored before and during treatment, as appropriate. Treatment should start with a 200-mg infusion on the first day, followed by one 100-mg infusion a day for at least 4 days and no more than 9 days. Remdesivir is recommended for a conditional marketing authorisation, one of the EU regulatory mechanisms to facilitate early access to medicines that fulfil an unmet medical need, including in emergency situations in response to public health threats such as the current pandemic. This type of approval allows the Agency to recommend a medicine for marketing authorisation with less complete data than normally expected, if the benefit of a medicine’s immediate availability to patients outweighs the risk inherent to the fact that not all the data are yet available. In order to better characterise the effectiveness and safety of remdesivir, the company will have to submit the final reports of the remdesivir studies to the Agency by December 2020, and further data on the quality of the medicine, as well as the final data on mortality, by August 2020. As for all medicines, a risk management plan (RMP) will ensure rigorous safety monitoring of remdesivir once authorised across the EU. Further efficacy and safety data will be collected through on-going studies and post-marketing reports and will be regularly reviewed by the CHMP and EMA’s safety committee (PRAC). Since April 2020, the PRAC has also been reviewing safety data on patients treated outside clinical studies, which are being submitted as monthly safety reports; these will continue to be submitted and assessed after the medicine is on the market. During the assessment of remdesivir, the CHMP had the support of experts from the COVID-19 EMA pandemic task force (COVID-ETF), which was established to bring together the most relevant expertise from the European medicines regulatory network to assist Member States and the European Commission in dealing with the development, authorisation and safety monitoring of medicines and vaccines against COVID-19. The European Commission, which was kept informed by EMA throughout the evaluation, will fast-track the decision-making process and aims to grant a decision on the conditional marketing authorisation for remdesivir in the coming week, allowing the product to be marketed in the EU. Contact point EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

Under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed COVID-19 vaccine development and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines. The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June 2020. Many researchers around the world are currently working on vaccines against COVID-19 but a rapid authorisation of COVID-19 vaccines will only be possible if robust and sound scientific evidence on vaccine candidates’ quality, safety and efficacy is generated. International convergence of data requirements is intended to encourage and accelerate the development of vaccines as a global public health good. During the workshop, global regulators focused on requirements for non-clinical and clinical data from early phase studies that are needed before proceeding with advanced (phase 3) clinical trials with COVID-19 vaccine candidates in humans. They exchanged views on key aspects, such as eligibility criteria for inclusion of diverse populations, primary endpoints and other methodological considerations related to the design of phase 3 clinical trials. Meeting participants agreed that regulatory convergence, to the extent possible, on certain key aspects of phase 3 clinical trial designs will help developers to generate robust evidence on the quality, safety and efficacy of potential COVID-19 vaccines that meets the needs of regulators around the globe. This is critical for expediting and streamlining global development and authorisation of vaccines against COVID-19. The meeting built on the experience and knowledge gained from the first workshop on COVID-19 vaccine development held in March 2020, which underlined the urgency of conducting clinical trials with COVID-19 vaccine candidates in humans and international regulators’ commitment to exchange information about the global efforts towards developing vaccines against COVID-19. The second workshop brought together 100 participants from more than 20 countries, representing 28 medicines regulatory authorities and the World Health Organization. The workshop was moderated by Dr Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy at EMA, and Dr Marion Gruber, Director of Office of Vaccines Research & Review at the US FDA. More details on the discussions and the outcomes of the meeting will be shared in the coming days. Contact: EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

The European medicines regulatory network has issued recommendations on impurities in medicines following the conclusion of an exercise to draw on lessons learnt from the presence of nitrosamines in a class of blood pressure medicines known as sartans. The recommendations aim to clarify the roles and responsibilities of companies involved in the manufacture of medicines and to amend guidance on controlling impurities and good manufacturing practice. The recommendations also cover the management of impurities once detected, communication with patients and healthcare professionals, and international cooperation. The full recommendations are available on EMA’s website. The network noted that nitrosamines were not previously recognised as potential impurities in sartan medicines, and these recommendations will help both regulators and companies better prevent and mitigate the risks of these and other impurities in the future. Nitrosamines are classified as probable human carcinogens (substances that could cause cancer) based on animal studies. Regulators in the EU first became aware that they were present in some sartan medicines in mid-2018. The discovery led to swift regulatory action, including the recall of medicines and measures to stop the use of active substances from certain manufacturers. A subsequent EU review, which concluded in April 2019, established the sources of nitrosamines and set out new manufacturing requirements for sartans. Although the exercise focused on nitrosamines in sartans, the recommendations will help reduce the risk of impurities being present in other medicines and ensure that regulators are better prepared to manage cases of unexpected impurities in the future. In September 2019, EMA launched an Article 5(3) procedure to provide additional guidance to companies that make and market medicines in the EU. The recommendations of the lessons learnt exercise will complement the outcome of this Art 5(3) procedure which will provide the key scientific opinion on the presence of nitrosamine impurities in human medicines containing chemically synthesised active substances. Reviewing practices on the basis of experience is one of the ways the authorities in the EU ensure that medicines in the EU are of the highest quality. EU authorities will continue working closely with the European Directorate for the Quality of Medicines & HealthCare and international partners and will take necessary measures to protect and reassure patients. Contact point EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News